Share AtaiBeckley Buyout – Minichart

Eli Lilly presented Phase 1 data for its investigational ADC sofetabart mipitecan (Sofe-M) plus bevacizumab in platinum-sensitive ovarian cancer, showing a 79% objective response rate and 100% disease control rate. The study included 33 patients, with responses consistent across prior treatments. Sofe-M demonstrated a safety profile consistent with known profiles of each medicine. The company is conducting three global Phase 3 trials for Sofe-M in ovarian cancer.

Eli Lilly presented Phase 1 data for its investigational drug sofetabart mipitecan (Sofe-M) in combination with bevacizumab for platinum-sensitive ovarian cancer. The trial showed a 79% confirmed objective response rate and 100% disease control rate. Sofe-M is being studied in multiple Phase 3 trials under the FRAmework-01 program. The drug targets folate receptor alpha (FRα), which is highly expressed in ovarian cancer cells.

Eli Lilly (LLY) presented Phase 1 data for its investigational drug sofetabart mipitecan (Sofe-M) plus bevacizumab, showing a 79% objective response rate and 100% disease control rate in platinum-sensitive ovarian cancer. The study included 33 patients, with responses consistent across FRα expression levels and prior PARP inhibitor exposure. Sofe-M is being studied in multiple Phase 3 trials under the FRAmework-01 program.

Eli Lilly's experimental drug, sofetabart mipitecan (Sofe-M), showed promising results in a Phase 1 study for ovarian cancer, with a 100% disease control rate in patients. Sofe-M, an FRα-targeting antibody-drug conjugate, is being studied in multiple Phase 3 trials. The company aims to address the unmet need in platinum-sensitive ovarian cancer treatment.

Eli Lilly and Company (LLY) has begun construction on a $5 billion manufacturing facility near Richmond, VA, as part of a $50 billion US expansion plan. The site will produce active pharmaceutical ingredients (API) and finished medicines, including antibody-drug conjugates (ADCs) for cancer and autoimmune treatments. The project is expected to create 650 jobs and will use advanced technologies like AI and machine learning.

Eli Lilly and Hong Kong-listed METiS TechBio have partnered to develop AI-driven lipid nanoparticle drug delivery technologies. METiS could receive up to $1.1 billion in milestone payments and royalties. The collaboration aims to improve tissue targeting and therapeutic performance.